Haleon (HLN) “Could be a Mini Kenvue,” Says Jim Cramer

Core Insights - Haleon plc (NYSE:HLN) is experiencing mixed performance, with struggles in North America but strong growth in Latin America and India [2] - The company reported a 0.4% growth in US same-store sales, contrasting with the 1.4% decline that analysts had predicted, indicating a tight consumer economy [2] - Haleon's defensive product line, Sensodyne, saw revenue growth, while discretionary brands experienced a drop in sales [2] - Jim Cramer suggested that Haleon could be likened to a "mini Kenvue," highlighting its potential without the controversies associated with Kenvue [3] Company Performance - Haleon plc sells consumer products, including toothpaste and pain relief items, under well-known brands like Sensodyne and Panadol [2] - The third-quarter earnings report showed a 0.4% increase in US same-store sales, which was better than the expected 1.4% decrease [2] - The performance in North America contrasts with the strong growth in other regions, particularly Latin America and India [2] Market Position - The company is positioned in a tight consumer economy, with mixed results across its product lines [2] - Cramer’s commentary suggests that Haleon has potential as an investment, although there are other AI stocks that may offer higher returns [3]